These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21406657)

  • 21. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
    Hameed O; Chhieng D; Adams AL
    J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
    Dolan M; Snover D
    Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation on parallel HER-2 testing using in situ hybridization and immunohistochemistry in breast cancer tissues].
    Pan XY; Gao HY; Zhang JL; Fu WT; Liu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2225-7. PubMed ID: 19923073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
    Huang W; Reinholz M; Weidler J; Yolanda L; Paquet A; Whitcomb J; Lingle W; Jenkins RB; Chen B; Larson JS; Tan Y; Sherwood T; Bates M; Perez EA
    Am J Clin Pathol; 2010 Aug; 134(2):303-11. PubMed ID: 20660336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Mehta RS; Schubbert T
    J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
    [No Abstract]   [Full Text] [Related]  

  • 27. [Quality control of HER2 immunohistochemistry--results from a Hungarian study].
    Cserni G; Kálmán E; Kulka J; Orosz Z; Udvarhelyi N; Krenács T
    Magy Onkol; 2007; 51(1):23-9. PubMed ID: 17417672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correspondence re: Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
    Hugh J; Barley R; Dabbagh L
    Mod Pathol; 2001 Mar; 14(3):263. PubMed ID: 11266538
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Lottner et al. simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005; 205: 577-584.
    Szollosi Z; Egervari K; Nemes Z; Kaczur V
    J Pathol; 2005 Sep; 207(1):119-20; author reply 121-2. PubMed ID: 15920704
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunohistochemical detection of c-erbB-2 oncoprotein in patients with breast cancer.
    Chariyalertsak S; Chariyalertsak S; Cheirsilpa A; Sugano K; Ohkura H
    J Med Assoc Thai; 1996 Nov; 79(11):715-21. PubMed ID: 8997010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A
    J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
    [No Abstract]   [Full Text] [Related]  

  • 32. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
    Penault-Llorca F; Vincent-Salomon A; MacGrogan G; Roger P; Treilleux I; Valent A; Mathieu MC; Antoine M; Becette V; Bor C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Devouassoux M; Fiche M; Fondrevelle ME; Fridman V; Garbar C; Genin P; Ghnassia JP; Haudebourg J; Laberge-Le Couteulx S; Loussouarn D; Maran-Gonzalez A; Marcy M; Michenet P; Poulet B; Sagan C; Trassard M; Verriele V; Arnould L; Lacroix-Triki M;
    Ann Pathol; 2014 Oct; 34(5):352-65. PubMed ID: 25439988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
    Ellis MJ
    J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
    [No Abstract]   [Full Text] [Related]  

  • 36. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
    Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
    Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practice guidelines released for HER2 testing in breast cancer.
    Oncology (Williston Park); 2007 Jan; 21(1):2. PubMed ID: 17313154
    [No Abstract]   [Full Text] [Related]  

  • 39. [Dual color in situ hybridization in HER2 testing].
    Horii R
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():423-7. PubMed ID: 23350435
    [No Abstract]   [Full Text] [Related]  

  • 40. New peptide vaccine for HER2-expressing breast tumors.
    Rochman S
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25677037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.